- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03315832
Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study (ARISTOTE)
Aortic stenosis (AS) is the most frequent valvular heart disease in Western countries, with increasing prevalence. Recent guidelines recommend aortic valve intervention (surgical aortic valve replacement [SAVR] or transcatheter aortic valve replacement [TAVR]) in severe AS, as soon as symptoms or left ventricular (LV) dysfunction occur, in order to improve clinical outcome and achieve LV mass (LVM) regression. The highest amount of LVM regression is obtained during the first year. Nevertheless, there is heterogeneity in LV remodeling and residual LV hypertrophy is associated with poorer postoperative improvement in cardiac function and morphology. Incomplete regression of LV hypertrophy at 12 months after SAVR is a powerful predictor of adverse outcome. Yet, the use of specific pharmacological therapy to improve postoperative LVM regression could be an appealing therapeutic option after aortic valve intervention.
Renin-angiotensin-aldosterone system blockers (RAASb) and more particularly angiotensin-II receptor blockers (ARBs) are efficient in reducing LVM in hypertensive patients, as emphasized by several meta-analyses. In addition, ARBs improve myocardial relaxation, diastolic function, decreased hypertrophy and may have anti-fibrotic effects. In a recent retrospective study from our group, RAASb prescription after SAVR was associated with increased survival, but confirmation through a randomized trial is mandatory. In a prospective randomized single-center study, the use of candesartan was associated both with LV and LA remodeling as compared to the conventional management. Nevertheless, these results are based on echocardiographic data, which is not the gold standard for the assessment cardiac remodeling, and no placebo or active comparator was tested to control the impact of ARBs in these patients.
The primary objective of this Phase II study is to investigate the efficacy of valsartan, introduced postoperatively, as compared to placebo, on 1-year changes in indexed LVM, as assessed by CMR, in patients undergoing aortic valve intervention (SAVR or TAVR) for AS.
The secondary objectives are to compare the efficacy of valsartan vs. placebo in terms of one-year changes (difference from baseline) in cardiac function and in cardiac morphology, one-year exercise capacity and one-year changes in biomarkers related to cardiac function. In addition, the assessment of the safety of valsartan will also be considered as secondary objective.
The ARISTOTE trial is a multicenter prospective phase II, randomized, double-blind study including patients with the diagnosis of severe AS and indication for valve intervention.
The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist.
Patients will be randomized between 2 groups (valsartan versus placebo) and the treatment will be initiated (80 mg daily) at 5±4 days following aortic valve intervention. The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
The patients will be cautiously monitored and any adverse events will be collected. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study. The tolerance will be regularly assessed and dose adjusted according to a pre-specified algorithm.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Victor ABOYANS, MD
- Phone Number: +33 555058953
- Email: victor.aboyans@chu-limoges.fr
Study Contact Backup
- Name: Julien MAGNE, PhD
- Phone Number: +33 555056310
- Email: julien.magne@chu-limoges.fr
Study Locations
-
-
-
Limoges, France, 87042
- Limoges university hospital
-
Contact:
- Victor ABOYANS, MD
- Phone Number: +33 555058953
- Email: victor.aboyans@chu-limoges.fr
-
Contact:
- Julien MAGNE, PhD
- Phone Number: +33 555056310
- Email: julien.magne@chu-limoges.fr
-
Principal Investigator:
- Victor ABOYANS, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men with age ≥18 years
- Women at postmenopausal state as defined by absence of menses for the last 12 months without alternative medical cause.
- Severe AS, defined according most recent guidelines (aortic valve area <1.0cm² or <0.6cm²/m² and aortic mean pressure gradient ≥40mmHg or aortic maximal velocity >4m/s, as assessed using transthoracic echocardiography [TTE]).
- Indication for aortic valve intervention
- Affiliation to the French Social Security system
- Signed informed consent.
Exclusion Criteria:
- Patients already under any Renin-Angiotensin-Aldosterone System blockers (RAASb) prior to randomization.
- Concomitant coronary artery bypass graft or other valvular intervention
- Other significant left-sided valvular heart diseases (≥moderate), even without concomitant procedure
- Any contra-indication to CMR
- Chronic kidney disease with estimated glomerular filtration rate (GFR) <30 ml/min
- Prior or planned organ transplantation
- Hyperkaliemia (kaliemia >5.5 mmol/L at inclusion visit)
- Severe hepatic failure, biliary cirrhosis, cholestasis
- Combined use of aliskiren and concomitant diabetes mellitus or renal failure with GFR<60mL/min/1.73m²
- Low systolic blood pressure (<100mmHg)
- History of angioedema
- History of hypersensitivity or allergy to Angiotensin-II Receptor Blockers or excipient
- Under legal authority.
- Unwilling to consent
Secondary Exclusion Criteria:
- Patients not under RAASb prior to randomization but who should benefit from this treatment to improve outcome:
- Heart failure with reduced ejection fraction (<40%)
- Coronary artery disease
- Clinical peripheral artery disease
- History of cerebrovascular disease
- Uncontrolled hypertension despite the use of other therapeutic classes
- Diabetes mellitus
- Impossibility to perform randomization into the 9-day post-intervention period due to per procedural complication with prolonged stay in intensive cardiac care unit (including death).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Valsartan
The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist.
The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention.
The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
|
The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist.
The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention.
The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
|
Placebo Comparator: Placebo Oral Tablet
The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode.
Patient in the control group will receive a placebo using the same protocol as the valsartan group.
|
The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode.
Patient in the control group will receive a placebo using the same protocol as the valsartan group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Indexed left ventricular mass
Time Frame: Day 0 to Year 1
|
the 1-year change from baseline in indexed LVM after aortic valve intervention as assessed using cardiac magnetic resonance (CMR)
|
Day 0 to Year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left ventricular global longitudinal strain
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in left ventricular global longitudinal strain quantified using CMR
|
Day 0 to Year 1
|
Left ventricular global longitudinal strain
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in Left ventricular global longitudinal strain quantified using transthoracic echocardiography (TTE)
|
Day 0 to Year 1
|
Left atrial volume
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in Left atrial volume quantified using CMR
|
Day 0 to Year 1
|
Left atrial volume
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in Left atrial volume quantified using TTE
|
Day 0 to Year 1
|
Indexed left ventricular mass
Time Frame: Day 0 to Year 1
|
the 1-year change from baseline in indexed LVM after aortic valve intervention as assessed using TTE (real-time 3D)
|
Day 0 to Year 1
|
Native T1
Time Frame: Day 0 to Year 1
|
the 1-year change from baseline in native T1 using CMR
|
Day 0 to Year 1
|
Rate of late gadolinium enhancement (LGE)
Time Frame: Day 0 to Year 1
|
the 1-year change from baseline in rate of LGE using CMR
|
Day 0 to Year 1
|
Volume of late gadolinium enhancement (LGE)
Time Frame: Day 0 to Year 1
|
the 1-year change from baseline in volume of LGE using CMR
|
Day 0 to Year 1
|
Extra cellular volume
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in extra cellular volume using CMR
|
Day 0 to Year 1
|
Indexed interstitial volume
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in Indexed interstitial volume using CMR
|
Day 0 to Year 1
|
Electrocardiographic strain
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in Electrocardiographic strain
|
Day 0 to Year 1
|
Left ventricular ejection fraction
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in Left ventricular ejection fraction using CMR
|
Day 0 to Year 1
|
Left ventricular ejection fraction
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in Left ventricular ejection fraction using TTE
|
Day 0 to Year 1
|
Peak exercise VO2
Time Frame: Year 1
|
The 1-year measurement of Peak exercise VO2
|
Year 1
|
VE/VCO2 ratio
Time Frame: 1 year
|
The 1-year measurement of VE/VCO2 ratio
|
1 year
|
Maximal load
Time Frame: 1 year
|
The 1-year maximal load reached
|
1 year
|
New-York heart association functional class
Time Frame: 1 year
|
The 1-year assessment of New-York heart association functional class
|
1 year
|
Exercise oscillatory ventilation rate
Time Frame: 1 year
|
The 1-year quantification of exercise oscillatory ventilation rate
|
1 year
|
Nt-pro Brain natriuretic peptide
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in level of Nt-pro Brain natriuretic peptide using immunoassay
|
Day 0 to Year 1
|
Plasma cardiac troponin I
Time Frame: Day 0 to Year 1
|
The 1-year change from baseline in concentration of Plasma cardiac troponin I using high-sensitivity assay
|
Day 0 to Year 1
|
Incidence of treatment-Emergent Adverse Events
Time Frame: Day 1 to Month 13
|
Clinical occurrence of adverse events (AEs) and serious adverse events (SAEs) during the duration of the study period ending month 13
|
Day 1 to Month 13
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Cardiomegaly
- Aortic Valve Stenosis
- Hypertrophy
- Constriction, Pathologic
- Hypertrophy, Left Ventricular
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Valsartan
Other Study ID Numbers
- I16007 (ARISTOTE)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Hospices Civils de LyonRecruiting
-
Edwards LifesciencesActive, not recruitingHeart Failure | Aortic Stenosis | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral StenosisUnited States, Canada, Poland
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
Clinical Trials on Valsartan
-
Qingdao Central HospitalNot yet recruitingMyocardial Infarction | HypertensionChina
-
Novartis PharmaceuticalsCompleted
-
Damanhour UniversityTanta UniversityCompleted
-
Yuhan CorporationCompletedHypertension | HyperlipidemiaKorea, Republic of
-
Novartis PharmaceuticalsCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States, Canada
-
Novartis PharmaceuticalsCompletedHypertensionSweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Diabetes Mellitus | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism | Natriuretic PeptidesUnited States
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone SystemUnited States
-
Shanghai Pharmaceuticals Holding Co., LtdRecruitingDiabetic Kidney DiseaseChina
-
NovartisCompleted